A new study reveals that a patient-derived organoid model demonstrates TP53-dependent sensitivity to gemcitabine in spinal chordoma. This finding could inform future treatment strategies for patients with this rare cancer.
patient derived organoid model identifies tp53 dependent gemcitabine sensitivity in spinal chordoma
Original title: “A patient-derived organoid model identifies TP53-dependent gemcitabine sensitivity in spinal chordoma.”